Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

The establishment of Hua Medicine’s pharmaceutical sales and marketing team resulted in significant sales growth in the first two months of 2025, opening a new model of innovative drug ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

In its fourth quarter 2024 investor letter, RiverPark Large Growth Fund emphasized stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company ...

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

The firm uses market research and key criteria such as the price-to-sales ratio to identify undervalued ... is a well-known American multinational pharmaceutical firm that has a long history ...

Indian pharmaceutical ... sales, profit margins may shrink due to intense competition in the US generics market. Additionally, regulatory risks persist, with compliance issues, warning letters ...

The USD/CAD pair trades on a flat note near 1.4320 during the late American session on Tuesday. The pair consolidates in a ...

RARE opened at $37.82 on Tuesday. Ultragenyx Pharmaceutical has a fifty-two week low of $36.71 and a fifty-two week high of $60.37. The stock has a fifty day moving average of $41.64 and a 200-day ...

Fintel reports that on March 18, 2025, Evercore ISI Group initiated coverage of West Pharmaceutical Services (NYSE:WST) with a Outperform recommendation. Analyst Price Forecast Suggests 23.04% ...

Much has been written about the demise of the traditional pharmaceutical sales model and the “Complex Buying Environment” that now pervades within our industry. The reasons have been well docu ...